The publication of this article supports the REVERT consortium’s research efforts to revolutionize treatment selection for patients with inoperable metastatic metastatic colorectal cancer (mCRC) through advanced AI-based decision support systems and innovative technologies.
The REVERT project brings together a dynamic consortium of 22 research centers, biobanks, clinical facilities and 4 SMEs from 5 European countries, collaborating to create an AI-based system that generates an ordered list of treatment options.
What makes the REVERT decision support system truly unique is its ability to generate this ordered list of treatment options for clinicians. The system provides personalized treatment recommendations and promotes AI principles of explainability and trust.
We invite you to read the full article here.